Introduction
During recent years a number of new /J-lactam antibiotics have been introduced into clinical practice. Some of these compounds are monobactams. The prototype of this class is aztreonam (Brogden & Heel, 1986 ) which has antibacterial activity against a wide range of aerobic Gram-negative organisms. Since after systemic administration, aztreonam concentrations in cerebrospinal fluid (CSF) in the presence of normal and inflamed meninges exceed the inhibitory and bactericidal concentrations for most Gram-negative bacteria, the antibiotic is effective in the treatment of Gram-negative bacterial meningitis caused by susceptible organisms (Scheld et al., 1983; Duma et al., 1984; Modai et al., 1986) .
Carumonam is a new N-sulphonated monocyclic /?-lactam antibiotic with activities in vivo and in vitro comparable to those of aztreonam (Imada et al., 1985) .
Many experimental studies and several pieces of clinical evidence consider the convulsive effects of /Mactam antibiotics (Semel & Allen, 1991; De Sarro et al., 1983 Eng et al., 1989) . /3-Lactam antibiotics were able to induce convulsions in various animal species when administered in high doses (De Sarro et al., 1983 , 1995a and their convulsant action has been principally attributed to the inhibition of Tel: +39-90-671749; Fax: +39-90-661029. GABA system (Antoniadis, Muller & Wollert, 1980; De Boer, Stoof & Van Duyn, 1980; Hori et al., 1985) . In our previous study we demonstrated that following intracerebroventncular (icv) administration in rats the most convulsant compound of a series of /Mactam antibiotics was cefazolin; aztreonam induced less marked effects than cefazolin (De Sarro et al., 1995a) . Recently we have also described a different pattern of responsiveness to cefazolin and carbapenems in different strains of mice, the genetically epilepsy-prone Dilute Brown Agouti DBA/2J (DBA/2) mouse and Swiss or C57 mice (De Sarro et al., 1993, 19956) .
The DBA/2 mouse has been known since 1947 to be susceptible to audiogenic seizures (Hall, 1947) . DBA/2 mice undergo an age-dependent sequence of convulsions when exposed to a loud mixed-frequency sound (12-16 kHz; 90-120 db) such as a door bell (Chapman, Croucher & Meldrum, 1984) . DBA/2 mice (16-30 days old), show in response to a loud tone, an ill-coordinated locomotion consisting of wild running followed by rhythmic clonic jerking, with the animal lying on one side, followed by tonic flexion and tonic extension of trunk, limbs and tail. The latter phase may terminate with respiratory arrest and death. In addition, it has been reported that mature DBA/2 mice which, with maturity, develop resistance to sound-induced seizures (Chapman et al., 1984) , still have an increased seizure susceptibility to a variety of non-audiogenic convulsant treatment including chemical and physical stimuli (Chapman et al., 1984 (Chapman et al., , 1987 Engstrom & Woodbury, 1988; De Sarro et al., 1993 , 1994 . The nature of audiogenic seizures in DBA/2 mice has been studied extensively and neurochemical abnormalities have been described by various authors (Chapman & Meldrum, 1985) . Thus, this strain of mice is considered an excellent animal model for the study of certain kinds of human epilepsy and for testing convulsant or anticonvulsant drugs (Chapman et al., 1984 (Chapman et al., , 1987 Seyfried & Glaser, 1985) .
Since we postulated that carumonam, likewise aztreonam, might be able to elicit seizures, the intention of the present study was to investigate the possible seizure-like activity of carumonam as compared with the convulsant activity induced by aztreonam in DBA/2, Swiss and C57 mice.
Methods

Drugs
Aztreonam was obtained from Menarini (Firenze, Italy); carumonam (sodium salt) was obtained from Bracco, (Milano, Italy) . The drugs were dissolved in isotonic sterile saline for ip administration (0.1 mL/10 g body weight) and in sodium phosphate buffer 67 raM for icv injection (5 /iL/mouse).
Testing of convulsant activity
DBA/2 (16-24g, 42-48 days old), Swiss (18-28 g, 42-48 days old) and C57 mice (18-28 g, 42-48 days old) were purchased from Charles River (Calco, Como, Italy). Mice of each strain were injected with aztreonam (0.91-6.89 mmol/kg ip and 0.49-4.9/imol/mouse icv) or carumonam (1.31-6.89 mmol/kg ip and 0.49-4.9 /^mol/ mouse icv) and then placed in a plexiglass box (40 x 40 x 30 cm) and observed for 120 min after ip administration or 60 min after icv injection of drug. For icv injections, mice were anesthetized with ether and injections were made in the left or right lateral ventricle (coordinates 1 mm posterior and 1 mm lateral to the bregma; depth 2.4 mm) using a 10 fih Hamilton microsyringe (type 70IN) fitted with a nylon cuff on the needle as described previously (De Sarro, Meldrum & Nistico, 1988) . Injection of drugs by this procedure led to a uniform distribution throughout the ventricular system within 10 min (De Sarro et al., 1988) . For each dose of monobactam derivative eight to ten animals of each strain were used. The intensity of seizure response (SR) was scored on the following scale: 0 = no response, 1 = wild running, 2 = clonus, 3 = tonus, 4 = respiratory arrest, which is identical to that observed after auditory stimulation (De Sarro et al., 1993) .
For ethical reasons, animals which had seizures were killed with ether anaesthesia at the end of experiments.
Electrocortical analysis
Electrocortical (ECoG) activity was recorded (8 channel ECoG machine OTE Biomedica, Florence, Italy) through four chronically-implanted steel screw electrodes, inserted bilaterally onto the frontoparietal area. At least three mice, treated with the largest dose of carumonam and aztreonam (4.59, 5.74 and 6.89 mmol/Kg ip), were studied for changes in ECoG activity.
Statistical analysis
Statistical comparisons among groups of control and drug-treated animals were made using Fisher's exact probability test (incidence of the seizure phases) or Mann-Whitney U-test (median seizure score ± interquartile range). The percentage incidence of each phase of the seizure was determined for each dose of aztreonam or carumonam administered using the method of Litchfield & Wilcoxon (1949) . CD*) (convulsant dose) values (with 95% confidence limits) for each compound and each phase of seizure response were estimated using the method of Litchfield & Wilcoxon (1949) by an IBM computer program; the relative convulsant activities were determined by comparison of respective CDM values. Table I shows that the intensities of the seizures were significantly different in the three strains of mice studied after ip administration of aztreonam. In particular, DBA/2 mice were more susceptible to convulsant doses of aztreonam than Swiss or C57 mice. Higher doses of aztreonam were necessary in Swiss or C57 mice to induce a similar incidence of the clonic phase of the seizures, whilst the tonic phase of the seizures was observed with minor incidence (Table I ). The CD W and LDso values of aztreonam in DBA/2 mice, in Swiss and in C57 mice are reported in Table III . three strains of mice after ip administration of carumonam. In particular, DBA/2 mice were more susceptible to convulsant doses of carumonam than Swiss or C57 mice. Rare myoclonic jerks were observed only following carumonam doses of 2.10 and 3.44 mmol/kg ip in 2 out of 10 and 4 out of 10 DBA/2 mice respectively; no tonic seizures were observed. Conversely, no behavioural epileptic signs were observed in Swiss and C57 mice administered with carumonam doses of 2.10 and 3.44 mmol/kg ip. The CDJO and LDso values of carumonam in DBA/2 mice, in Swiss mice and in C57 mice are reported in Table III .
Results
Effects of aztreonam administration in Swiss, CS1 mice and in audiogenic seizure-prone DBA 12 mice
Effects of carumonam administration in C57 mice, Swiss mice and in audiogenic seizure prone DBA 12 mice
Comparative convulsant properties ofaztreonam and carumonam in DBA 12 mice following intracerebroventricular administration
As reported in Table IV aztreonam appeared slightly more potent than carumonam, but no significant behavioural differences were observed following icv injection of the two monobactams studied in DBA/2 mice. The CDM value of aztreonam for inducing clonus was 2.74 (2.11-3.75 /^mol/mouse), whilst that of carumonam was 2.83 (1.97-4.08 /zmol/mouse). In addition, the CD50 value of aztreonam for inducing tonus Groups of DBA/2, Swiss or C57 mice were randomly assigned to experimental gToups of ten animals and injected ip with the stated doses of aztreonam. The animals were observed for 120 min after drug injection. Incidence of each seizure phase is expressed as the percentage of mice in each group displaying that phase. Significant differences in the incidence of seizure phases between vehicle and drug-treated mice are denoted by *P < 0.05; **P < 0.01 using Fisher's exact probability test. M.S.S., Median seizure score; I.R., interquartile range. Significant differences in median seizure score between DBA/2 and Swiss or C57 mice are denoted by *P < 0.05 using Mann Whitney U-test. Groups of DBA/2, Swiss or C57 mice were randomly assigned to experimental groups of ten animals and injected ip with the stated doses of carumonam. The animals were observed for 120 min after drug injection. Incidence of each seizure phase is expressed as the percentage of mice in each group displaying that phase. Significant differences in the incidence of seizure phases between vehicle and drug-treated mice are denoted by *P < 0.05; **P < 0.01 using Fisher's exact probability test. M.S.S., Median seizure score; I.R., interquartile range. Significant differences in median seizure score between DBA/2 and Swiss or C57 mice are denoted by *P < 0.05 using Mann Whitney U-test. was 3.55 (2.66-4.75 /imol/mouse), whilst that of carumonam was 4.15 (2.71-6.34 mouse).
Electrocortical activity in DBA 12 mice
The electrocorticographic epileptic pattern was similar in DBA/2 mice which received an equimolar dose (4.59 mmol/Kg ip) of carumonam or aztreonam (Figures 1 and 2 ).
Discussion
The present study confirms that C57, Swiss and DBA/2 mice show a different susceptibility to seizures induced by convulsants such as aztreonam and carumonam. In particular, seizure latency was consistently shorter in DBA/2 than in Swiss or C57 mice; the seizure intensity was also different in the three mouse strains. In Swiss and C57 mice an increased latency to clonic and tonic phase was observed following aztreonam or carumonam administration. These data suggest that the neural mechanisms which delay or prevent the onset of clonic seizures are not yet present in 42-48 days old DBA/2 mice. These findings are in agreement with previous studies Litchfield & Wilcoxon (1949) . All data are expressed as mmol/kg ip. ND, Not detectable. which showed that DBA/2 mice have an increase seizure susceptibility to a variety of non-audiogenic convulsant (chemical and physical) treatments (Chapman et al., 1984 (Chapman et al., , 1987 Engstrom & Woodbury, 1988; De Sarro et al., 1993) . Studies of the disposition and metabolism of aztreonam and carumonam in different animal species demonstrated that they are similar (Kripalani et al., 1984; Singhvi et al., 1984; Yoshida et al., 1986 ). 
Groups of DBA/2 mice were randomly assigned to experimental groups of 10 animals and injected icv with the stated doses of aztreonam or carumonam alone. The animals were observed for 60 min after drug injection. The incidence of each seizure phase is expressed as the percentage of mice in each group displaying that phase. M.S.S., Median seizure score; I.R., interquartile range. Hydrolysis of the /?-lactam ring, yielding open-ring metabolites, is common to /?-lactam antibiotics and it was suggested that the neurotoxicity of imipenem may have been caused by its accumulated open metabolite, which has a seizure potential similar to that of cephazolin (Dudley, 1986; Tse, Hernandez-Vera & Desai, 1987) . Thus, although these metabolites were found to be devoid of any significant antimicrobial activity (Kripalani et al., 1984) , they could be involved in the seizure-like activity induced by aztreonam and carumonam.
The pharmacokinetics of monobactam antibiotics also deserves to be considered. Aztreonam penetrates the CSF adequately in the presence of either inflamed or non-inflamed meninges, achieves potentially therapeutic levels and maintains these levels for prolonged periods of time (Duma et al., 1984) . An interesting study, carried out on the distribution of (14C) aztreonam in rat tissue, showed that the concentrations of total radioactivity in meninges were equal to or higher than those in serum at the later time points (6 and 24 h) . These data suggest that the elimination of aztreonam from the CSF appears to be somewhat slower than that from serum, and consequently, the duration of activity of aztreonam might be longer than that predicted on the basis of the rate of decline of aztreonam levels in serum. Since as mentioned above the disposition and metabolism of aztreonam and carumonam in different animal species is similar, we suggest that CNS pharmacokinetics of both compounds may play a determinant role in inducing seizures with the inhibition of GABA neurotransmission (Antoniadis et al., 1980; De Boer et al., 1980; Hori et al., 1985) . The convulsant action of /Mactam derivatives has been related to the reduction of GABA release from nerve terminals or to the inhibition of the GABA binding to its receptor sites (Antoniadis et al., 1980; De Boer et al., 1980; Hori et al., 1985; Williams, Bennett & Comereski, 1988; Eng et al., 1989) . Although the previous authors believe that the convulsant effects of /Mactam derivatives are mainly related to inhibition of the GABA system, an alternative hypothesis may be considered i.e. the involvement of other neurotransmitters systems. We have recently demonstrated that some amino acid excitatory antagonists are able to antagonize the seizures induced by imipenem in mice (De Sarro et al., 1995c) .
The possibility that /?-lactam antibiotics possess agonistic or modulatory properties at receptors activated by excitatory amino acids might be an alternative explanation to the GABAergic one which requires experimental confirmation. Since previous studies have indicated that systemic administration of /J-lactam derivatives to experimental animals or to humans may sometimes produce epileptogenic effects (De Sarro et al., 1983 Tse et al., 1987; Eng et al., 1989) , we conclude that physicians should consider the minor epileptogenic activity of these two monobactams when treating patients with predisposing epileptic factors.
